News | June 04, 2012

GE, Affibody AB Collaborate on PET Imaging Agent for Breast, Gastric Cancer

June 4, 2012 GE Healthcare signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

Future clinical trials will investigate the confirmation of Her2 status in patients with breast cancer recurrence, to determine if Her 2 status changes over time, monitor therapy of patients with metastatic breast cancer receiving anti-Her2 treatments, and help resolve indeterminate Her2 tests. These studies, if positive, could ultimately pave the way for better targeting of anti-Her2 therapies to those patients most likely to benefit.

“The partnership brings together the best of several distinct offerings – GE Healthcare’s market expertise in the global PET market, industrialization and commercialization and Affibody’s expertise in generating high-affinity binders and initial clinical data,” Marivi Mendizabal, head of research for GE Healthcare, medical diagnostics. “We expect a productive collaboration with leading academics and the pharma industry to help this research reach its full potential.”

“We are very pleased to continue our relationship with GE Healthcare from the preclinical to the clinical setting and look forward to collaborating with a world-leading partner”, commented David Bejker, CEO of Affibody. “Our clinical data, the first of which was presented at the 34th San Antonio Breast Cancer Symposium last December, is the result of collaborative research with leading academics and has led us to believe that a Her2-targeted PET imaging agent may benefit many cancer patients.”

For more information: www.gehealthcare.com, www.affibody.se

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Overlay Init